2024
Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting
Hofmeister C, Zhang M, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Sborov D. Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting. Blood 2024, 144: 5152-5152. DOI: 10.1182/blood-2024-202100.Peer-Reviewed Original ResearchNon-Hispanic blacksNon-Hispanic whitesSurveillance Epidemiology and End ResultsNational Cancer InstituteWhite patientsBlack menBlack patientsAvailability of diagnosisWhite menStudy start dateEncounter dateSEER dataFace-to-faceHealth systemMultiple myeloma patientsMyeloma patientsOutpatient encountersDeath reportingAge decileSocial Vulnerability IndexWhite womenMatched control groupBlack womenMedian survivalPatient records
2023
Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study
Theprungsirikul P, Liu Y, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study. Blood 2023, 142: 7364. DOI: 10.1182/blood-2023-186985.Peer-Reviewed Original ResearchFront-line treatmentBone marrow plasma cellsCommunity practice settingsR-ISS stageECOG performance statusRetrospective observational studyPerformance statusTransplant eligibilityPractice settingsCytogenetic abnormalitiesBone lesionsInsurance typeObservational studyTreatment responseEastern Cooperative Oncology Group performance statusInternational Myeloma Working Group criteriaYale New Haven Health SystemInternational Staging System stageRefractory multiple myeloma patientsUnfavorable-risk cytogeneticsGood partial responseFront-line therapyCD38 monoclonal antibodyMultiple myeloma patientsBetter treatment responseAn Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma
Williams L, Khosravi B, Velimirovic M, Khouri J, Raza S, Mazzoni S, Samaras C, Awada H, Dima D, Valent J, Anwer F. An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma. Blood 2023, 142: 1990. DOI: 10.1182/blood-2023-188762.Peer-Reviewed Original ResearchProgression free survivalMultiple myeloma patientsTreatment selectionFree survivalMyeloma patientsSurvival outcomesMultiple myelomaFrontline autologous stem cell transplantationDisease progressionProgression free survival valuesAutologous stem cell transplantationMedian progression free survivalNewly diagnosed multiple myelomaPrognostic modelSurvival analysisRetrospective dataStem cell transplantationFirst line treatmentDepth of responseDiagnosed multiple myelomaLog-rank testRandomized controlled clinical trialTime of diagnosisPatient related factorsNon-progressive casesComparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristicsOutcomes with panobinostat in heavily pretreated multiple myeloma patients
Pan D, Mouhieddine T, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars In Oncology 2023, 50: 40-48. PMID: 37005144, DOI: 10.1053/j.seminoncol.2023.03.006.Peer-Reviewed Original ResearchConceptsMultiple myelomaStandard-of-care therapyResponse rateTriple-class refractory diseaseHigh-risk cytogeneticsClinical benefit rateMedian overall survivalProgression-free survivalRefractory multiple myelomaMultiple myeloma patientsHistone-deacetylase inhibitorsDescending order of frequencyMount Sinai HospitalOral optionOverall survivalRefractory diseaseMyeloma patientsBenefit ratePanobinostatAcademic medical centerTriple classPatientsMyelomaAgent combinationsSinai Hospital
2022
Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology.
Karagoz K, Ayers K, Patel B, Wells J, Newman S, Oh W, Zhou X, Chen R, Guin S. Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology. Journal Of Clinical Oncology 2022, 40: 6584-6584. DOI: 10.1200/jco.2022.40.16_suppl.6584.Peer-Reviewed Original ResearchTumor mutational burdenOverall survivalCancer typesTargetable mutationsPatient outcomesNext-generation sequencingNGS resultsSingle large healthcare systemElectronic medical record dataPositive NGS resultsTMB-low patientsOutcomes of patientsStage 4 patientsMultiple myeloma patientsLung cancer patientsSignificant survival differenceGenomic alterationsStage 3Medical record dataLarge healthcare systemMicrosatellite instability statusRelevant clinical questionsNCCN guidelinesClinical responseTreatment landscape
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT)
Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT). Transplantation And Cellular Therapy 2021, 27: s362-s363. DOI: 10.1016/s2666-6367(21)00464-4.Peer-Reviewed Original Research
2020
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Luo M, Usmani S, Mateos M, Nahi H, Chari A, San‐Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun Y, Parasrampuria D. Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. The Journal Of Clinical Pharmacology 2020, 61: 614-627. PMID: 33145788, PMCID: PMC8048619, DOI: 10.1002/jcph.1771.Peer-Reviewed Original ResearchConceptsSubcutaneous formulation of daratumumabIncidence of neutropeniaIntravenous daratumumabMonotherapy studiesCombination therapySubcutaneous daratumumabPK samplingStandard-of-care regimensPeak-to-trough fluctuationHigher trough concentrationsCombination therapy studiesSafety end pointMultiple myeloma patientsPopulation pharmacokinetic analysisCycle 1Flat doseExposure-response analysesMyeloma patientsDaratumumabTrough concentrationsSubcutaneous formulationPharmacokinetic analysisTreatment periodTherapy studiesNeutropenia
2019
PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES
Carniti C, Biancon G, Banfi S, Vella C, Magni M, Pennisi M, Anna D, Guidetti A, Corradini P. PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES. HemaSphere 2019, 3: 599-600. DOI: 10.1097/01.hs9.0000563532.69483.ec.Peer-Reviewed Original ResearchCell-free DNADLBCL patientsIgH gene rearrangementTumor burdenResidual diseaseIgH rearrangementsGene rearrangementsDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaLarge B-cell lymphomaPossible disease progressionPossible residual diseaseR-CHOP therapyBaseline plasma samplesLymph node biopsyDisease monitoringImmunoglobulin heavy chain gene rearrangementMultiple myeloma patientsNon-invasive disease monitoringCell lymphoma patientsNumber of patientsFFPE samplesPET-CT scan
2018
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study
Biancon G, Gimondi S, Vendramin A, Carniti C, Corradini P. Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study. Journal Of Molecular Diagnostics 2018, 20: 859-870. PMID: 30165206, DOI: 10.1016/j.jmoldx.2018.07.006.Peer-Reviewed Original ResearchConceptsTumor plasma cellsMultiple myelomaPlasma cellsResidual diseasePlasma samplesPilot studySecond-line therapyCell-free tumor DNA analysisMultiple myeloma patientsConventional laboratory parametersSerial plasma samplesMinimal residual diseaseBone marrow aspirateNumber of PCsTumor DNA analysisA Pilot StudyClonal IgH rearrangementsClonal IgH gene rearrangementsIgH gene rearrangementTumor clonotypesComplete responseLaboratory parametersMyeloma patientsCfDNA levelsTumor levels
2016
Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements
Gimondi S, Biancon G, Vendramin A, Zaninelli S, Rizzitano S, Malan S, Bermema A, Montefusco V, Carniti C, Corradini P. Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements. Blood 2016, 128: 4430. DOI: 10.1182/blood.v128.22.4430.4430.Peer-Reviewed Original ResearchCell-free tumor DNAMinimal residual diseaseIgH gene rearrangementMultiple myeloma patientsTime pointsTumor burdenMyeloma patientsGene rearrangementsLiquid biopsyPlasma samplesInternational Myeloma Working Group Uniform Response CriteriaTime of CRSequential plasma samplesBone marrow infiltrationDisease monitoringResidual tumor burdenNon-invasive strategyImmunoglobulin gene rearrangementsMM ptsPresence of subclonesSpecific clonotypesProgressive diseaseMarrow infiltrationMRD monitoringResidual disease
2015
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors
Dulmovits BM, Appiah-Kubi AO, Papoin J, Hale J, He M, Al-Abed Y, Didier S, Gould M, Husain-Krautter S, Singh SA, Chan KW, Vlachos A, Allen SL, Taylor N, Marambaud P, An X, Gallagher PG, Mohandas N, Lipton JM, Liu JM, Blanc L. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood 2015, 127: 1481-1492. PMID: 26679864, PMCID: PMC4797024, DOI: 10.1182/blood-2015-09-667923.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle Cellbeta-GlobinsCarrier ProteinsErythroid Precursor CellsErythropoiesisFetal Hemoglobingamma-GlobinsGene Expression Regulation, DevelopmentalGenetic VectorsHematopoietic Stem CellsHistone DemethylasesHumansIkaros Transcription FactorKruppel-Like Transcription FactorsLentivirusMultiple MyelomaNeoplasm ProteinsNuclear ProteinsProteasome Endopeptidase ComplexRepressor ProteinsRNA InterferenceRNA, Small InterferingSOXD Transcription FactorsThalidomideTranscription, GeneticConceptsSickle cell anemiaCell anemiaΓ-globinThird-generation immunomodulatory drugAdult human erythroblastsMultiple myeloma patientsHematopoietic progenitorsΓ-globin levelsΓ-globin repressionCurrent therapeutic strategiesErythroid differentiation programFetal hemoglobinAdult hematopoietic progenitorsPomalidomide treatmentImmunomodulatory drugsMyeloma patientsTranscriptional reprogrammingFetal hemoglobin productionTranscription networksTherapeutic strategiesDifferentiation programPomalidomideHuman erythroblastsΒ-hemoglobinopathiesGenetic ablationFluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.Peer-Reviewed Original ResearchHigh-dose influenza vaccineHigh-dose vaccinePlasma cell disordersNovel vaccination strategiesProtective HAI titersCell-mediated immunityMultiple myeloma patientsNovel vaccine strategiesInfluenza vaccineVaccination strategiesSignificant unmet needInfluenza vaccinationHAI titersPCD patientsCell disordersFlu seasonSecondary endpointsSeroprotection ratesDose vaccineMyeloma patientsVaccine strategiesFlu infectionUnmet needInfection rateGrade 2 adverse events
2014
Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
Korde N, Dosani T, Simakova O, Mailankody S, Costello R, Roschewski M, Yuan C, Stetler-Stevenson M, Figg W, Landgren O, Maric I. Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. Blood 2014, 124: 2080. DOI: 10.1182/blood.v124.21.2080.2080.Peer-Reviewed Original ResearchIndependent data monitoring committeeMultiple myeloma patientsNon-CR groupsPlasma cellsMyeloma patientsData monitoring committeeMFI ratioCR groupCombination therapyPre-treatment bone marrow samplesResponse rateProteasome levelsMinimal residual disease statusGood partial response rateProgression-free survival dataMonitoring committeeMean fluorescence intensity ratioNovel flow cytometric assayBone marrow plasma cellsCarfilzomib-based therapyComplete response/Mean percentage declinePatient's good responsePartial response rateResidual disease status
2011
Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities,
Munshi N, Lee S, Kambhampati S, Rose M, Mohiuddin A, Efebera Y, Han A, Houranieh A, Zimelman A, Brophy M, Prabhala R, Grady T, Mehta P, Hayes T, Yellapragada S, Behler C, Klein C, Roodman D, Lichtenstein A. Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities,. Blood 2011, 118: 3964. DOI: 10.1182/blood.v118.21.3964.3964.Peer-Reviewed Original ResearchOverall response rateNewly diagnosed multiple myeloma patientsEntity's Board of DirectorsGrade 2 neuropathyMultiple myeloma patientsSignificant co-morbiditiesCo-morbiditiesMyeloma patientsOlder patientsEvaluate overall response rateAutologous stem cell transplantationGrade 1 neuropathyGrade 3 neuropathyStem cell transplantationProportion of patientsSingle-arm studyHistory of cancerAssociated with toxicityAdvisory CommitteeVeterans HospitalWeekly bortezomibBortezomib doseDexamethasone regimenWeekly regimenDexamethasone doseEfficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study.
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Grady T, Klein C, Mehta P, Hayes T, Roodman G, Lichtenstein A. Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. Journal Of Clinical Oncology 2011, 29: 8074-8074. DOI: 10.1200/jco.2011.29.15_suppl.8074.Peer-Reviewed Original Research
2010
Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Saba H, Klein C, Mehta P, Hayes T, Roodman D, Lichtenstein A. Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities. Blood 2010, 116: 3061. DOI: 10.1182/blood.v116.21.3061.3061.Peer-Reviewed Original ResearchEntity's Board of DirectorsGrade 1 neuropathyMultiple myeloma patientsSignificant co-morbiditiesOverall response rateCo-morbiditiesMyeloma patientsNewly-diagnosed multiple myeloma patientsNewly diagnosed multiple myeloma patientsEvaluate overall response rateAutologous stem cell transplantationElevation of serum creatinineResponse rateGrade 3 neuropathyRegimen of bortezomibDose of bortezomibAssociated with side effectsStem cell transplantationImproved toxicity profileProportion of patientsOlder patient populationHistory of cancerAdvisory CommitteeWeekly bortezomibBortezomib dose
2006
Outpatient high‐dose melphalan in multiple myeloma patients
Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients. Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmbulatory CareAnti-Bacterial AgentsAntibiotic ProphylaxisAntineoplastic Agents, AlkylatingBacteremiaCeftriaxoneDose-Response Relationship, DrugFeverHospitalizationHumansIncidenceLength of StayMelphalanMiddle AgedMultiple MyelomaNeutropeniaRetrospective StudiesStaphylococcal InfectionsStem Cell TransplantationConceptsHigh-dose melphalanOnset of neutropeniaPrimary care providersOutpatient settingMean durationPeripheral blood progenitor cell infusionGeneral outpatient settingProgenitor cell infusionTreatment-related mortalityMultiple myeloma patientsUse of ceftriaxoneApparent beneficial effectTransplant episodesMost patientsCell infusionFebrile patientsMedian timeMyeloma patientsRandomized trialsDecreased riskOutpatient therapyAmbulatory therapyOutpatient treatmentNeutropeniaCare providers
2003
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCombined Modality TherapyCyclophosphamideDatabases, FactualDexamethasoneDoxorubicinFemaleFeverGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansLeukapheresisMaleMiddle AgedMultiple MyelomaNeutropeniaPeripheral Blood Stem Cell TransplantationRetrospective StudiesTransplantation, AutologousVincristineConceptsMultiple myelomaEnough stem cellsCells/Autologous stem cell rescueFever/neutropeniaG-CSF beginningStem cell rescueHigh-dose chemotherapyPotential transplant candidatesMultiple myeloma patientsStem cell collectionStem cell toxicityStem cellsAggressive chemotherapyInitial therapyTransplant candidatesAgent therapyConsecutive patientsExcessive morbidityMyeloma patientsCell mobilizationCell rescuePatientsG-CSFCell collection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply